The DEA Telemedicine Cliff
Controlled-Substance Remote Prescribing & the Recurring Expiration
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Governed by Ryan Haight Act (2008); DEA telemedicine flexibilities
Reference only. Not medical advice.
What can go wrong
If the flexibility lapses or a permanent rule imposes an in-person evaluation requirement, the no-visit remote TRT model would face a compliance gap. Patients should understand that the regulatory basis for their prescription pathway is a temporary federal accommodation, not settled permanent law.
This is something to take to a clinician. The Atlas can tell you what is known about the dea telemedicine cliff in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Testosterone is a Schedule III controlled substance under the Controlled Substances Act. The 2008 Ryan Haight Act generally requires an in-person medical evaluation before a controlled substance is prescribed online. During COVID-19, the DEA waived that requirement, which is what made fully-remote, no-in-person-visit telehealth TRT possible at scale. According to DEA and HHS notices, that flexibility has been extended repeatedly rather than made permanent.
The entire cash-pay TRT model rests on a flexibility that keeps almost expiring.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 prohibits delivering, distributing, or dispensing a controlled substance by means of the internet without a valid prescription, and defines a valid prescription as one issued after at least one in-person medical evaluation. The COVID-19 public health emergency triggered an exception. The DEA and HHS have since issued a series of temporary extensions of those telemedicine flexibilities rather than finalizing a permanent rule.
What the marketing skips
Cash-pay telehealth TRT clinics that advertise no in-person visit depend entirely on this waiver remaining in force. The DEA describes the goal of repeated extensions as avoiding a telemedicine cliff that would disrupt care for patients relying on remote prescribing. The agencies have stated they are still reviewing public comments on permanent rules. A proposed framework floated a special registration and, in some drafts, referral or in-person requirements for certain prescriptions; the final shape is not settled.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks. The remote-prescribing pathway for controlled substances such as testosterone is governed by federal rules that have been extended on a temporary basis.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
DEA / HHS joint notices
The agencies state the extensions are intended to avoid disrupting care while permanent rules are finalized.
Telehealth platforms profit from low-friction, high-volume remote prescribing. Brick-and-mortar clinics and the in-person evaluation requirement represent the alternative cost structure that the waiver lets platforms avoid.
What we do not know
- Will the DEA finalize a permanent telemedicine rule, and will it require an in-person or referral component for controlled substances?
- How would a special-registration regime change who can prescribe testosterone remotely?
- Would a lapse force existing patients to obtain an in-person evaluation to continue therapy?
At a glance
- Testosterone schedule
- Schedule III (DEA)
- Governing law
- Ryan Haight Act, 2008
- Current flexibility window
- Through Dec 31, 2026 (per DEA/HHS, fourth extension)
- Effect if it lapses
- In-person exam required before remote Rx
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about The DEA Telemedicine Cliff. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.